Journal of Reproduction & Infertility

Journal of Reproduction & Infertility

Female Fertility Preservations, Clinical and Experimental Options

Authors
Zahra Rajabi 1
Fereshteh Aliakbari 2
Hossein Yazdekhasti 3
1 Department of Biomedical Engineering, University of Virginia, Virginia, USA; Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 Infertility and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Recently, due to tremendous progress in prognosis, diagnosis, and treatment of different kinds of malignancies, demands on fertility preservation were raised significantly in developed countries. Fertility failure is one of the most detrimental consequences of radio/cytotoxic treatment procedures in women who could overcome their cancer disease. For women who are involved in cancer diseases, there are multiple options regarding their fertility preservation and those could be selected according to patient’s age, the risk of ovarian involvement, the available time and the type of cancer with different levels of advantages and disadvantages. Although there are multiple options, but embryo cryopreservation and ovarian tissue cryopreservation are the most reliable methods for pre-mature and post-mature puberty, respectively. In addition, other approaches like artificial ovary, isolation and cryopreservation of follicles and mature and immature oocyte preservation are under investigations and the success rate of oocyte vitrification is increasing. Therefore, the techniques have the potential to be used in clinic in near future. The presence of comprehensive consultation, before the onset of any kind of cancer treatment procedures, is an indispensable issue which would help patients to make up their mind in choosing the immediate and the best available fertility preservation option.
Keywords
Cancer treatment
Cryopreservation
embryo
Fertility preservation
Freezing
oocyte
Ovarian tissue
Transplantation
  1. Horner M, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al. SEER cancer statistics review [internet]. Bethesda, MD: National Cancer Institute; 1975-2006 [cited 2018 Jan 21]. Available from: https://seer.cancer.gov/csr/1975_2006/
  2. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101(1):3-27.
  3. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174-83.
  4. Greenlee RT, Hill‐Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51(1):15-36.
  5. Kim SS. Oocyte biology in fertility preservation. 1st ed. USA: Springer; 2013. 97 p.
  6. Apperley J, Reddy N. Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy. Blood Rev. 1995;9(2):93-116.
  7. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7(6):535-43.
  8. Tschudin S, Bitzer J. Psychological aspects of fertility preservation in men and women affected by cancer and other life-threatening diseases. Hum Reprod Update. 2009;15(5):587-97.
  9. Donnez J. Fertility preservation in women, focusing on cancer, benign diseases and social reasons. Minerva Ginecol. 2018;70(4):385-6.
  10. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500-10.
  11. Kawamura K, Kawamura N, Hsueh AJ. Activation of dormant follicles: a new treatment for premature ovarian failure? Curr Opin Obstet Gynecol. 2016;28(3):217-22.
  12. Suzuki N, Yoshioka N, Takae S, Sugishita Y, Tamura M, Hashimoto S, et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod. 2015;30(3):608-15.
  13. Yazdekhasti H, Rajabi Z. Established and Future Promising Fertility Preservation Options in Adolescence and Adults. Int Med Med Investig J. 2017;3(1):1-7.
  14. Gidoni Y, Holzer H, Tulandi T, Tan SL. Fertility preservation in patients with non-oncological conditions. Reprod Biomed Online. 2008;16(6):792-800.
  15. Rezaeian Z, Yazdekhasti H, Nasri S, Rajabi Z, Fallahi P, Amidi F. Effect of selenium on human sperm parameters after freezing and thawing procedures. Asian Pac J Reprod. 2016;5(6):462-6.
  16. Bedoschi G, Oktay K. Current approach to fertility preservation by embryo cryopreservation. Fertil Steril. 2013;99(6):1496-502.
  17. Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril. 2013;99(6):1476-84.
  18. Roque M, Lattes K, Serra S, Sola I, Geber S, Carreras R, et al. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril. 2013;99(1):156-62.
  19. Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2011;96(2):277-85.
  20. Cobo A, Meseguer M, Remohí J, Pellicer A. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod. 2010;25(9):2239-46.
  21. Cobo A, Remohí J, Chang C-C, Nagy ZP. Oocyte cryopreservation for donor egg banking. Reprod Biomed Online. 2011;23(3):341-6.
  22. Donnez J, Dolmans MM, Pellicer A, Diaz-Garcia C, Serrano MS, Schmidt KT, et al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertil Steril. 2013;99(6):1503-13.
  23. Wu J, Zhang L, Wang X. In vitro maturation, fertilization and embryo development after ultrarapid freezing of immature human oocytes. Reproduction. 2001;121(3):389-93.
  24. Toth TL, Lanzendorf SE, Sandow BA, Veeck LL, Hassen WA, Hansen K, et al. Cryopreservation of human prophase I oocytes collected from unstimulated follicles. Fertil Steril. 1994;61(6):1077-82.
  25. Sánchez M, Alamá P, Gadea B, Soares SR, Simón C, Pellicer A. Fresh human orthotopic ovarian cortex transplantation: long-term results. Hum Reprod. 2007;22(3):786-91.
  26. Nugent D, Meirow D, Brook P, Aubard Y, Gosden R. Transplantation in reproductive medicine: previous experience, present knowledge and future prospects. Hum Reprod Update. 1997;3(3):267-80.
  27. Kim SS, Battaglia DE, Soules MR. The future of human ovarian cryopreservation and transplantation: fertility and beyond. Fertil Steril. 2001;75(6):1049-56.
  28. Dolmans MM, Donnez J, Camboni A, Demylle D, Amorim C, Van Langendonckt A, et al. IVF outcome in patients with orthotopically transplanted ovarian tissue. Hum Reprod. 2009;24(11):2778-87.
  29. Rajabi Z, Yazdekhasti H, Noori Mugahi SMH, Abbasi M, Kazemnejad S, Shirazi A, et al. Mouse preantral follicle growth in 3D co-culture system using human menstrual blood mesenchymal stem cell. Reprod Biol. 2018;18(1):122-31.
  30. Rajabi Z, Khokhar Z, Yazdekhasti H. The Growth of preantral follicles and the impact of different supplementations and circumstances: a review study with focus on bovine and human preantral follicles. Cell Reprogram. 2018;20(3):164-77.
  31. Jensen AK, Macklon KT, Fedder J, Ernst E, Humaidan P, Andersen CY. 86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children. J Assist Reprod Genet. 2017;34(3):325-36.
  32. Williams RS, Littell RD, Mendenhall NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer. 1999;86(10):2138-42.
  33. Tulandi T, Al-Took S. Laparoscopic ovarian suspension before irradiation. Fertil Steril. 1998;70(2):381-3.
  34. Thomas P, Winstanly D, Peckham M, Austin D, Murray M, Jacobs H. Reproductive and endocrine function in patients with Hodgkin's disease: effects of oophoropexy and irradiation. Br J Cancer. 1976;33(2):226-31.
  35. Hunter M, Glees J, Gazet JC. Oophoropexy and ovarian function in the treatment of Hodgkin's disease. Clin Radiol. 1980;31(1):21-6.
  36. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod. 1996;11(8):1620-6.
  37. Pacheco BP, Ribas JM, Milone G, Fernandez I, Kvicala R, Mila T, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol. 2001;81(3):391-7.
  38. Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig. 1999;6(5):229-39.
  39. Gosden RG, Wade JC, Fraser HM, Sandow J, Faddy MJ. Impact of congenital or experimental hypogonadotrophism on the radiation sensitivity of the mouse ovary. Hum Reprod. 1997;12(11):2483-8.
  40. Jr TGD, JENISON EL. Presence and characteristics of receptors for [D-Trp6] luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol. 1998;12(3):489-98.
  41. Otala M, Suomalainen L, Pentikäinen MO, Kovanen P, Tenhunen M, Erkkilä K, et al. Protection from radiation-induced male germ cell loss by sphingosine-1-phosphate. Biol Reprod. 2004;70(3):759-67.
  42. Carmely A, Meirow D, Peretz A, Albeck M, Bartoov B, Sredni B. Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice. Hum Reprod. 2009;24(6):1322-9.
  43. Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C, et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med. 2009;15(10):1179-85.
  44. Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017;377(17):1657-65.
  45. Oktay K, Nugent D, Newton H, Salha O, Chatterjee P, Gosden RG. Isolation and characterization of primordial follicles from fresh and cryopreserved human ovarian tissue. Fertil Steril. 1997;67(3):481-6.
  46. Sonmezer M, Oktay K. Fertility preservation in female patients. Human Reprod Update. 2004;10(3):251-66.
  47. Leporrier M, Von Theobald P, Roffe JL, Muller G. A new technique to protect ovarian function before pelvic irradiation: heterotopic ovarian autotransplantation. Cancer. 1987;60(9):2201-4.
  48. Donnez J, Kim SS. Principles and practice of fertility preservation. 1st ed. UK: Cambridge university press; 2011. 497 p.
  49. Chiti MC, Dolmans MM, Orellana R, Soares M, Paulini F, Donnez J, et al. Influence of follicle stage on artificial ovary outcome using fibrin as a matrix. Hum Reprod. 2015;31(2):427-35.
  50. Luyckx V, Dolmans M-M, Vanacker J, Legat C, Moya CF, Donnez J, et al. A new step toward the artificial ovary: survival and proliferation of isolated murine follicles after autologous transplantation in a fibrin scaffold. Fertil Steril. 2014;101(4):1149-56.
  51. Parvari S, Yazdekhasti H, Rajabi Z, Gerayeli Malek V, Rastegar T, Abbasi M. Differentiation of mouse ovarian stem cells toward oocyte-like structure by coculture with granulosa cells. Cell Reprogram. 2016;18(6):419-28.
  52. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004;428(6979):145-50.
  53. Asgari HR, Akbari M, Yazdekhasti H, Rajabi Z, Navid S, Aliakbari F, et al. Comparison of human amniotic, chorionic, and umbilical cord multipotent mesenchymal stem cells regarding their capacity for differentiation toward female germ cells. Cell Reprogram. 2017;19(1):44-53.
  54. Yazdekhasti H, Rajabi Z, Parvari S, Abbasi M. Used protocols for isolation and propagation of ovarian stem cells, different cells with different traits. J Ovarian Res. 2016;9(1):68.
  55. Yazdekhasti H, Hosseini MA, Rajabi Z, Parvari S, Salehnia M, Koruji M, et al. Improved isolation, proliferation, and differentiation capacity of mouse ovarian putative stem cells. Cell Reprogram. 2017;19(2):132-44.
  56. Yazdekhasti H, Hosseini J, Rajabi Z, Shirzeyli MH, Aliakbari F. Germline cells derived from mesenchymal stem cells, with the focus on Wharton's jelly. Asian PacJ Reprod. 2018;7(2):49-55.
  57. Reichman D, Man L, Park L, Lis R, Gerhardt J, Rosenwaks Z, et al. Notch hyper-activation drives trans-differentiation of hESC-derived endothelium. Stem Cell Res. 2016;17(2):391-400.
  58. Sandler VM, Lis R, Liu Y, Kedem A, James D, Elemento O, et al. Reprogramming human endothelial cells to haematopoietic cells requires vascular induction. Nature. 2014;511(7509):312-8.
  59. Aliakbari F, Sedighi Gilani MA, Yazdekhasti H, Koruji M, Asgari HR, Baazm M, et al. Effects of antioxidants, catalase and α-tocopherol on cell viability and oxidative stress variables in frozen-thawed mice spermatogonial stem cells. Artif Cells Nanomed Biotechnol. 2017;45(1):63-8.
  60. Aliakbari F, Yazdekhasti H, Abbasi M, Hajian Monfared M, Baazm M. Advances in cryopreservation of spermatogonial stem cells and restoration of male fertility. Microsc Res Tech. 2016;79(2):122-9.
  61. Aliakbari F, Gilani MA, Amidi F, Baazm M, Korouji M, Izadyar F, et al. Improving the efficacy of cryopreservation of spermatogonia stem cells by antioxidant supplements. Cell Reprogram. 2016;18(2):87-95.
  62. Polak de Fried E, Notrica J, Rubinstein M, Marazzi A, Gonzalez MG. Pregnancy after human donor oocyte cryopreservation and thawing in association with intracytoplasmic sperm injection in a patient with ovarian failure. Fertil Steril. 1998;69(3):555-7.
Journal of Reproduction & Infertility
Volume 19, Issue 3
Summer 2018
Pages 125-132